Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal disease

Journal of Renal Nutrition

Volumn 6, Issue 1, 1996, Pages 2-11

  Makoff, Rhoda ^a   Dwyer, Johanna ^b   Rocco, Michael V ^c  

^a R and D Laboratories Inc   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002423449     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-2276(96)90102-8     Document Type: Review

References (82)

1. Makoff R. Water-soluble vitamin status in patients with renal disease treated with hemodialysis or peritoneal dialysis. J Renal Nutr 1 2 (1991) 56-73
2. Stein G., Sperschneider S., and Koppe S. Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3 (1985) 52-62
3. Mydlik M., Derzsiova K., Valek A., et al. Vitamins and CAPD. Int Urol Nephrol 17 (1985) 281-286
4. Ramirez G., Chen M., Boyce Jr. H.W., et al. The plasma and red cell vitamin B levels of chronic hemodialysis patients: A longitudinal study. Nephron 42 (1986) 41-46
5. Ramirez G., Chen M., Boyce Jr. H.W., et al. Longitudinal follow-up of chronic hemodialysis patients without vitamin supplementation. Kidney Int 30 (1986) 99-106
6. Norris S.H., and Kurtzman N.A. Minimizing anemia in the chronic hemodialysis patient. Int Artif Organs 9 (1986) 199-208
7. Swainson C.P., and Winney R.J. Do dialysis patients need extra folate?. Lancet 1 (1983) 239
8. Rocco M., Poole D., Poindexter P., et al. Vitamin and mineral intake in stable chronic hemodialysis patients. JASN 6 (1995) 586
9. Ueland P.M., Refsum H., and Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis Jr. R.B. (Ed). Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function (1992), Dekker, New York, NY 183-236
10. Kang S.S., Wong P.W., and Malinow M.R. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 12 (1992) 279-298
11. Ubbink J.B., Vermaak W.J.H., van der Merwe A., et al. Vitamin B12, vitamin B6 and folate nutritional status in men with hyperhomocysteinemia. J Clin Nutr 57 (1993) 47-53
12. Bostom A.G., Shemin D., Lapane K.L., et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end stage renal disease patients on dialysis: A case-control study. Athersclerosis 114 (1995) 93-103
13. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 (1990) 458-482
14. Kopple J.D., and Swenseid M.E. Vitamin nutrition in patients undergoing maintenance hemodialysis. Kidney Int 8 (1975) 79-84 suppl 2
15. Descombes E., Hanc A., and Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 43 (1993) 1319-1328
16. Cunningham J., Sharman V.I., Goodwin F.J., et al. Do patients receiving haemodialysis need folic acid supplements?. Br Med J 282 (1981) 1582
17. Hemmeloff-Anderson K.E. Folic acid status of patients with chronic renal failure maintained by dialysis. Clin Nephrol 8 (1977) 510-513
18. Marumo F., Kamata K., and Okubo M. Deranged concentrations of water-soluble vitamins in the blood of undialyzed and dialyzed patients with chronic renal failure. Int J Artif Organs 9 (1986) 17-24
19. Spray G.H., Fourman P., and Witts L.J. The excretion of small doses of folic acid. Br Med J 2 (1951) 202-205
20. Gang V., Schulz R.J., Jult J., et al. Vitamin B6 Mangel und substitution bei chronischer. Uramie Klin Wochenschr 53 (1975) 335-338
21. Kasama R., Kock T., Canais-Navas C., et al. Vitamin B6 and hemodialysis. Proc Clin Nephrol Meet March (1995) A8
22. Waxman S., Corcino J.J., and Herbert V. Drugs, toxins and dietary amino acids affecting vitamin B12 or folic acid absorption or utilization. Am J Med 48 (1970) 599-608
23. Stone W.J., Warnock L.G., and Wagner C. Vitamin B6 deficiency in uremia. Am J Clin Nutr 28 (1975) 950-957
24. Jennette J.C., and Goldman I.D. Inhibition of the membrane transport of folates by anions retained in uremia. J Lab Clin Med 86 (1975) 834-843
25. Teehan B.P., Smith L.J., Sigler M.H., et al. Plasma pyridoxal-5′-phosphate levels and clinical correlations in chronic hemodialysis patients. Am J Clin Nutr 31 (1978) 1932-1936
26. Kleiner M.J., Tate S.S., Sullivan J.F., et al. Vitamin B6 deficiency in maintenance dialysis patients: Metabolic effects of repletion. Am J Clin Nutr 33 (1980) 1612-1619
27. Lacour B., Parry C., Drueke T., et al. Pyridoxal 5′-phosphate deficiency in uremic undialyzed, hemodialyzed and non-uremic kidney transplant patients. Clin Chim Acta 127 (1983) 205-215
28. Spannuth Jr. C.L., Warnock L.G., Wagner C., et al. Increased plasma clearance of pyridoxal 5′-phosphate in vitamin B6-deficient uremic man. J Lab Clin Med 90 (1977) 632-637
29. Kopple J., Mercurio J.D., Blumenkrantz M.J., et al. Daily requirement for pyridoxine supplements in chronic renal failure. Kidney Int 19 (1981) 694-704
30. Ross E.A., Shah G.M., Reynolds R.D., et al. Vitamin B6 requirements of patients on chronic peritoneal dialysis. Kidney Int 36 (1989) 702-706
31. Even a mild lack of B12 could hurt seniors. Tufts Nutr Lett 9 (1992) 11
32. Iseki K., Kawazoe N., Osawa A., et al. Survival analysis of dialysis patients in Okinawa Japan. Kidney Int 43 (1993) 404-409
33. Collins A.J., Hanson G., Umen A., et al. Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 15 (1990) 422-432
34. US Renal Data Systems. USRDS 1991 Annual Data Report. XX (August 1991), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
35. Allen R.H., Stabler S.P., Savage D.G., et al. Diagnosis of cobalamin deficiency. Usefulness of serum methylmalonic acid and total homocysteine concentration. Am J Hematol 34 (1990) 90-98
36. Savage D.G., Lindenbaum J., Stabler S.P., et al. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96 (1994) 236-246
37. Kopple J.D., Mercurio J.D., and Blumenkrantz M.J. Daily requirements for pyridoxine supplements in chronic renal failure. Kidney Int 19 (1988) 694-698
38. Selhub J., and Miller J.W. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsufuration of homocysteine. Am J Clin Nutr 55 (1992) 131-138
39. McCully K.S. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 (1969) 111-128
40. Mudd S.H., and Levy H.I. High levels of homocysteine from several inborn errors of metabolism: Disorders of transsulfuration. In: Stanbury J.B., Wyngaaden J.B., Frederickson D.S., et al. (Eds). The Metabolic Basis of Inherited Disease (1983), McGraw-Hill, New York, NY 458-503
41. Mudd S.H., Skovby F., Levy H.L., et al. The natural history of homocystinuria due to cystathionine beta synthase deficiency. Am J Hum Genet 37 (1985) 1-25
42. Selhub J., Jacques P.R., Wilson P.W., et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270 (1993) 2693-2698
43. Kang S.S., Wong P.W.K., and Norusis M. Homocysteinemia due to folate deficiency. Metabolism 36 (1987) 458-462
44. Hollowell Jr. J.G., Hall W.K., Coryell M.D., et al. Homocystinuria and organic aciduria in a patients with vitamin B12 deficiency. 7th International Congress on Nutrition and Metabolism in Renal Disease. Stockholm Sweden (1994) 102 (abstr)
45. Smolin L.A., and Benevenga N.G.H. Accumulation of homocysteine in vitamin B6 deficiency: A model for the study of cystathionine β synthase deficiency. J Nutr 112 (1982) 1264-1272
46. Steiner A. The effect of choline on the production of experimental atherosclerosis in rabbits. Proc Soc Exp Biol Med. XX 38 (1938) 231-233
47. Hartoff W.E., Ridout J.H., Sellers E.A., et al. Atheromatous changes in aorta, carotid and coronary arteries of choline deficient rats. Proc Soc Exp Biol Med. XX 81 (1952) 384-393
48. Murphy-Chutorian D.R., Wexman M.P., Grieco A.J., et al. Methionine intolerance: A possible risk factor for coronary artery disease. J Am Coll Cardiol 6 (1985) 725-730
49. Brattstrom L.E., Hardebo J.E., and Hultberg B.L. Moderate homocysteinemia-A possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 15 6 (1984) 1012-1016
50. Malinow M.R., Kang S.S., Taylor L.M., et al. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation 79 (1989) 1180-1188
51. Kang S.S., Wong P., Cook H.Y., et al. Protein-bound homocysteine: A possible risk factor for coronary artery disease. J Clin Invest 77 (1986) 1482-1486
52. Malinow M.R., Nieto F.J., Szklo M., et al. Carotid artery intimal medial wall thickening and plasma homocysteine in asymptomatic adults: The Atheroslerosis Risk in Communities Study. Circulation 87 (1993) 1107-1113
53. Selhub H., Jacques P.F., Bostom A.G., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332 (1995) 286-291
54. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 268 (1992) 877-881
55. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
56. Brattsstrom L.E., Israelsson B., Norrving B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 81 (1990) 51-60
57. Boers H.J., Smals A., Trijbels F.J.M., et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313 (1985) 709-715
58. Wall R.T., Harlan J.M., Harker L.A., et al. Homocysteine induced endothelial cell injury in vitro: A model for the study of vascular injury. Thrombosis Res 18 (1980) 113-121
59. Martin W.J. Neutrophils kill pulmonary endothelial cells by a hydrogen peroxide dependent pathway: An in vitro model of neutrophil mediated lung injury. Am Rev Resp Dis 130 (1984) 209-213
60. Sacks T., Moldow C.F., Craddoxk P.R., et al. Oxygen radical mediated endothelial cell damage by complement stimulated granuloycytes: An in vitro model of immune vascular damage. J Clin Invest 6 (1978) 1161-1167
61. Bunting S., Gyrglewski R., Mondaca S., et al. Arterial walls generate from protasglandin enedoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12 (1976) 897-913
62. Starkebaum G., and Harlan J.M. Endothelial cell injury due to copper catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77 (1986) 1370-1376
63. Wang J., Dudman N.P.B., and Wilcken D. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemotol 70 (1993) 1047-1052
64. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91 (1993) 308-318
65. Boers G.H.J. Hyperhomocysteinemia: A newly recognized risk factor for vascular disease. Neth J Med 45 (1994) 34-41
66. Partasarthy S. Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochem Biophys Acta 917 (1987) 337-340
67. Dudman N.P.B., Wilcken D., and Stocker R. Circulating lipid hydroperoxide levels in human hyper homocysteinemia: Relevance to development of arteriosclerosis. Arteriostler Thromb 13 (1993) 512-516
68. Lenz S.R., and Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88 (1991) 1906-1914
69. Parfrey P.S., and Harnett J.D. Long term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 23 (1994) 331-339
70. Rostand S.G., Kirk K.A., and Rutsky E.A. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22 (1982) 304-308
71. Wu G. Cardiovascular deaths among CAPD patients. Perit Dial Bull 4 (1993) S23 (suppl)
72. Soria C., Chadefaux B., Coude M., et al. Concentrations of total homocysteine in plasma in chronic renal failure. Clin Chem 36 (1990) 2137-2138
73. Ibels L.S., Steward J.F., Mahony J.F., et al. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. Q J Med NS 46 (1977) 197-214
74. Wilcken D., Dudman N.P.B., Tyrrell P.A., et al. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37 (1988) 697-701
75. Chauveau P., Chadefaux B., Coude M., et al. Hyperhomocysteinemia: A risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43 (1993) S72-S77 suppl 43
76. Hultberg B., Andersson A., and Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 40 (1993) 230-234
77. Jungers P., Chauveau P., Chadefaux B., et al. Hyperhomocysteinemia in chronic renal failure patients: Beneficial effect of folate supplementation. J Am Soc Nephrol 3 (1994) 332 (suppl)
78. Brattstrom L.E., Israelsson B., Jeppsson J.O., et al. Folic acid-An innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48 (1988) 215-231
79. Arnadottir M., Brattstrom L., Simonsen O., et al. The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40 (1993) 236-240
80. Bachmann J., Tepel M., Raidt H., et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6 (1995) 121-125
81. Janssen H.J.F.M., Stehouwer C., van den Berg M.J., et al. Folic acid lowers elevated homocysteine levels in chronic dialysis patients. Clin Nephrol 42 (1994) 136-137
82. Kim S.S., Hirose S., Tamura H., et al. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 10 (1994) 282-285